Study identifier:NIS-CPH-DUM-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A descriptive study of the efficacy and safety of ONGLYZA (Saxagliptin) under conditions of actual use in the Philippines
Type 2 Diabetes Mellitus
-
No
-
All
542
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|